---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-109998"
form_type: "8-K"
ticker: "REVB"
cik: "0001810560"
company_name: "REVELATION BIOSCIENCES, INC."
filed_at: "2024-09-27T23:59:59+00:00"
generated_at: "2026-05-31T01:14:44.734472+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Revelation Biosciences reports Gemini induces dose-dependent IL-10 increases up to 309-fold in Phase 1

## Summary
- Gemini induced statistically significant (p<0.05) dose-dependent IL-10 increases: 27-fold (low), 162-fold (mid), 309-fold (high) vs placebo at 2 hours.
- No significant increase in pro-inflammatory IL-1b and TNF-a, confirming TLR4 binding unique to Gemini.
- Data consistent with prior preclinical acute kidney injury models; supports potential in preventing AKI after cardiac surgery.
- Company plans to initiate Phase 1b study in late 2024.
- CEO James Rolke highlighted potential to fine-tune innate immune response and speed healing.

## SEC filing metadata
- accession: 0000950170-24-109998
- form_type: 8-K
- ticker: REVB
- cik: 0001810560
- company_name: REVELATION BIOSCIENCES, INC.
- filed_at: 2024-09-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810560/000095017024109998/0000950170-24-109998-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810560/000095017024109998/revb-20240924.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-109998
- JSON: https://secwatch.observer/filing/0000950170-24-109998.json
- Plain text: https://secwatch.observer/filing/0000950170-24-109998.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.